Welcome to our dedicated page for Intelligent Bio Solutions news (Ticker: INBS), a resource for investors and traders seeking the latest updates and insights on Intelligent Bio Solutions stock.
Intelligent Bio Solutions Inc. develops medical technology for rapid, non-invasive testing, centered on fingerprint sweat drug screening. Its updates commonly cover the Intelligent Fingerprinting Drug Screening System, Drug Screening Cartridges, DSR-Plus reader, lateral-flow test strip manufacturing, and the reader-and-consumable sales model used in workplace testing markets outside the United States.
Company news also focuses on clinical and regulatory work supporting an FDA 510(k) pathway for codeine detection, cybersecurity and validation testing tied to the system, European patent protection for fingerprint chemical analysis, manufacturing scale-up for readers and cartridges, customer deployments in the United Kingdom, and periodic revenue reports by product category.
Intelligent Bio Solutions Inc. (Nasdaq: INBS) has acquired Intelligent Fingerprinting Limited, enhancing its drug screening technology portfolio. As of September 30, 2022, the company reported a preliminary net loss of $1.21 million, improving from a $1.43 million loss during the same period last year, aided by government support income. The company is advancing its Biosensor development with two clinical studies for saliva glucose testing and is constructing a new manufacturing facility in Australia. A conference call is scheduled for today at 4:30 p.m. ET.
Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced the adoption of its fingerprint-based drug testing system by Glass Systems, a UK manufacturer. The system, capable of testing 1,000 employees across six sites, provides results in just ten minutes. This initiative aims to enhance workplace safety by enabling random and on-demand drug tests, ensuring employees are fit to operate machinery. The technology is positioned as a modern, non-invasive solution, promoting health and safety within the industry.
Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced that Eastern Airways will implement a new fingerprint sweat drug testing method to comply with European Aviation Authority regulations. This portable and hygienic test allows for rapid screening of employees to ensure fitness for work, promoting adherence to the company's Drug and Alcohol policy. The process takes under a minute for sample collection and provides results in ten minutes. The system can be utilized in-house, enhancing flexibility and compliance.
Intelligent Bio Solutions Inc. (Nasdaq: INBS) will release its first quarter financial results for the period ending September 30, 2022, on November 9, 2022, after market close. Management will conduct a conference call and webcast at 4:30 p.m. ET to discuss the results. The call will be accessible via a toll-free number and live webcast links. The company, known for its non-invasive testing solutions, is focused on delivering critical diagnostic tests for chronic diseases and has recently acquired Intelligent Fingerprinting, enhancing its portable drug testing capabilities.
Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced that Goldstar Transport has adopted fingerprint drug testing, replacing urine tests. This transition affects Goldstar's 600 drivers and aims to improve health and safety compliance across its 14 UK sites. The company purchased six Intelligent Fingerprinting portable readers for efficient in-house testing, yielding results in 10 minutes. The CEO of Intelligent Bio Solutions emphasized the rising importance of workplace screening amidst substance abuse concerns.